Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells

Cancer Research

Volumn 66, Issue 1, 2006, Pages 184-191

  Roccaro, Aldo Maria ^a   Hideshima, Teru ^a   Raje, Noopur ^a   Kumar, Shaji ^b   Ishitsuka, Kenji ^a   Yasui, Hiroshi ^a   Shiraishi, Norihiko ^a   Ribatti, Domenico ^c   Nico, Beatrice ^c   Vacca, Angelo ^c   Dammacco, Franco ^c   Richardson, Paul Gerard ^a   Anderson, Kenneth Carl ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BORTEZOMIB; FIBRONECTIN; INTERLEUKIN 6; MATRIGEL; PROTEASOME INHIBITOR; SOMATOMEDIN C; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ARTICLE; BONE MARROW CELL; CAPILLARY PROLIFERATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY RESISTANCE; TRANSCRIPTION REGULATION; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL GROWTH PROCESSES; CELLS, CULTURED; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENDOTHELIAL CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 31544433927     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1195     Document Type: Article

References (49)

1. Risau W. Mechanisms of angiogenesis. Nature 1997; 386:671-4.
2. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during angiogenesis. Microvasc Res 1977; 14:53-65.
3. Burri PH, Tarek MR. A novel mechanism of capillary growth in the rat pulmonary microcirculation. Anat Rec 1990;228:35-45.
4. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-63.
5. Hamada J, Cavanaugh PG, Lotan O. Separable growth and migration factors for large-lymphoma cells secreted by microvascular endothelial cells derived from organs for metastasis. Br J Cancer 1992;66:349-54.
6. Rifkin DB, Mignatti P. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73: 161-95.
7. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993;71:1368-83.
8. Chen C, Parangi S, Tolentino M. et al. A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res 1995;55:4230-3.
9. Folkman J. Angiogenesis inhibitors generated by tumors. Nat Med 1995;1:120-2.
10. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-7.
11. Bertolini F, Mancuso P, Gobbi A. et al. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol 2000;28:993-1000.
12. Vacca A, Ribatti D, Roncali L, et al Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-8.
13. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
14. Hayashi T, Hideshima T, Anderson KC. Novel therapies for multiple myeloma. Br J Haematol 2003;120: 10-7.
15. Hideshima T, Chauhan D, Podar K, et al Novel therapies targeting the myeloma cell and its bone marrow microenvironment Semin Oncol 2001;28:607-12.
16. Drexler HC, Risau W, Kondering MA, et al Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000;14:65-77.
17. Oikawa T, Sasaki T, Nakamura M, et al The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998;246:243-8.
18. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vitro and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
19. Dominici M, Campioni D, Lanza F, et al. Angiogenesis in multiple myeloma: correlation between in vitro endothelial colonies growth (CFU-En) and clinical-biological features. Leukemia 2001;15:171-6.
20. Hewett PW, Murray JC. Human lung microvessel endothelial cells: isolation, culture and characterization. Microvasc Res 1993;46:89-102.
21. Vacca A, Ria R, Semeraro F, et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 2003;102:3340-8.
22. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428-35.
23. Raje N, Kumar S, Hideshima T, et al Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004; 104:4188-93.
24. Iurlaro M, Vacca A, Minischetti M, et al Antiangiogenesis by cyclosporine. Exp Hematol 1998;26: 1215-22.
25. Vacca A, Iurlaro M, Ribatti D, et al. Antiangiogenesis is produced by non-toxic doses of vinblastine. Blood 1999;94:4143-55.
26. Kueng K, Silfer E, Eppenberger V. Quantification of cells cultured on 96-well plates. Anal Biochem 1989;182: 16-9.
27. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999; 103:1227-30.
28. Wilson L. Microtubules as drug receptors: pharmacological properties of microtubular protein. Ann N Y Acad Sci 1975;72:213-31.
29. Ribatti D, Gualandris A, Bastaki M, et al New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J Vase Res 1997;34:455-63.
30. Ribatti D, Urbinati C, Nico B, et al. Endogenous basic fibroblast growth factor is implicated in the vascularization of the chick embryo chorioallantoic membrane. Dev Biol 1995;170:39-49.
31. Reinmuth N, Fan F, Liu W, et al Impact of insulin-like growth factor receptor-1 function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 2002; 82:1377-89.
32. Beillard E, Pallisgaard N, van der Velden Vh. et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): Europe against cancer program. Leukemia 2003;17:2474-86.
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8.
34. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15: 1950-61.
35. Hideshima T, Chauahn D. Hayashi T, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 2003; 22:8386-93.
36. Podar K, Anderson K. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005;105:1383-95.
37. Keisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8:739-58.
38. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7:1419-28.
39. Teicher BA, Ara G, Herbst R, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5:2638-45.
40. Adamas J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
41. Orlowski RZ, Eswara JR, Lafond-Walker A, et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1999;58:4342-8.
42. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002;62:1083-6.
43. Nawrocki ST, Bruns CJ, Harbison MT, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002;1:1243-53.
44. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-5.
45. Vescio RA, Cao J, Hong CH, et al. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. J Immunol 1995;155:2487-97.
46. Vacca A, Ria R, Ribatti D, et al A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma Haematologica 2003;88:176-85.
47. Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001;86:23-33.
48. Seon BK. Expression of endoglin (CD105) in tumor blood vessels. Int J Cancer 2002;9:310-1.
49. Gerritsen ME, Tomlinson JE, Zlot C, et al. Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol 2003;140:595-610.